Rabbit Polyclonal Antibody to Detect a Pro-peptide Fragment of NSAID-activated Gene (NAG-1)/GDF15, a Protein Associated with Can
Posted May 23 2012 8:00pm
Description of Invention: Chronic inflammation is clearly associated with an increase in the risk of cancer. Non-steroidal anti-inflammatory drugs (NSAIDs) are well documented as agents that inhibit tumor growth and with long-term use can prevent tumor development. NSAID-activated gene (NAG-1), a unique member of the TGF-beta superfamily, is highly induced by NSAIDs and numerous drugs and chemicals with anti-tumorigenic activities.
The protein product of NAG-1 is first formed into an immature peptide dimer that must be cut at a specific site before it can be secreted as a mature protein. Currently available antibodies can only detect either the immature form of NAG-1 or the secreted mature protein, but do not recognize the peptide fragment that remains when the immature dimer is cut to form the mature protein. Now available for the first time, the present new antibody recognizes this NAG-1 pro-peptide fragment.
Applications: As a research tool to detect expression of the NAG-1/GDF15 cleavage fragment in cells and media from cultured cells.
Advantages: No other antibody is currently available to detect the NAG-1/GDF15 pro-peptide fragment.
Research Tool — Patent protection is not being pursued for this technology.
Related Technologies: EIR, Reference No. E-093-2011/0
Research Tool — Transgenic mice expressing human GDF15/Nag-1/Mic-1
Collaborative Research Opportunity: The NIEHS is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate or commercialize this antibody. For collaboration opportunities, please contact Elizabeth M. Denholm, Ph.D. at email@example.com .
For Licensing Information Please Contact: Patrick McCue Ph.D. NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: McCuepat@mail.nih.gov Phone: 301-496-7057 Fax: 301-402-0220